{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:43:43Z","timestamp":1784011423826,"version":"3.55.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["315969"],"award-info":[{"award-number":["315969"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["320107"],"award-info":[{"award-number":["320107"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["345326"],"award-info":[{"award-number":["345326"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2021-00154"],"award-info":[{"award-number":["2021-00154"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and hypothesis<\/jats:title>\n                  <jats:p>Breast cancer is more prevalent in women with severe mental illness than in the general population, and use of prolactin-increasing antipsychotics may be a contributing factor.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study design<\/jats:title>\n                  <jats:p>A nested case\u2013control study was conducted using the Swedish nationwide registers (inpatient\/outpatient care, sickness absence, disability pension, prescribed drugs, cancers). All women aged 18\u201385 years with schizophrenia\/schizoaffective\/other nonaffective psychotic disorder\/bipolar disorder and breast cancer (cases) were matched for age, primary psychiatric diagnosis, and disease duration with five women without cancer (controls). The association between cumulative exposure to prolactin-increasing\/prolactin-sparing antipsychotics and breast cancer was analyzed using conditional logistic regression, adjusted for comorbidities and co-medications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study results<\/jats:title>\n                  <jats:p>Among 132 061 women, 1642 (1.24%) developed breast cancer between 2010 and 2021, at a mean age of 63.3\u2005\u00b1\u200511.8 years. Compared with 8173 matched controls, the odds of breast cancer increased in women with prior exposure to prolactin-increasing antipsychotics for 1\u20134 years (adjusted odds ratio [aOR]\u2005=\u20051.20, 95% confidence interval [CI]\u2005=\u20051.03\u20131.41), and for\u2005\u2265\u20055 years (aOR\u2005=\u20051.47, 95%CI\u2005=\u20051.26\u20131.71). There were no increased or decreased odds of breast cancer with exposure to prolactin-sparing antipsychotics of either 1\u20134 years (aOR\u2005=\u20051.17, 95%CI\u2005=\u20050.98\u20131.40) or \u22655 years (aOR\u2005=\u20050.99, 95%CI\u2005=\u20050.78\u20131.26). The results were consistent across all sensitivity analyses (ie, according to different age groups, cancer types, and primary psychiatric diagnosis).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Although causality remains uncertain, exposure to prolactin-elevating antipsychotics for\u2005\u2265\u20051 year was associated with increased odds of breast cancer in women with severe mental illness. When prescribing antipsychotics, a shared decision-making process should consider individual risk factors for breast cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/schbul\/sbae058","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T14:00:07Z","timestamp":1714485607000},"page":"1471-1481","source":"Crossref","is-referenced-by-count":29,"title":["Antipsychotic Use and Risk of Breast Cancer in Women With Severe Mental Illness: Replication of a Nationwide Nested Case\u2013Control Database Study"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-7233","authenticated-orcid":false,"given":"Marco","family":"Solmi","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Ottawa , Ontario ,","place":["Canada"]},{"name":"SCIENCES LAB, Department of Mental Health, The Ottawa Hospital , Ontario ,","place":["Canada"]},{"name":"Ottawa Hospital Research Institute (OHRI), Clinical Epidemiology Program, University of Ottawa , Ontario ,","place":["Canada"]},{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa , Ontario ,","place":["Canada"]},{"name":"Department of Child and Adolescent Psychiatry, Charit\u00e9 Universit\u00e4tsmedizin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7244-145X","authenticated-orcid":false,"given":"Markku","family":"L\u00e4hteenvuo","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital , Kuopio ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3795-3126","authenticated-orcid":false,"given":"Antti","family":"Tanskanen","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital , Kuopio ,","place":["Finland"]},{"name":"Department of Clinical Neuroscience, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Center for Psychiatry Research, Stockholm City Council , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4192-853X","authenticated-orcid":false,"given":"Olivier","family":"Corbeil","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universit\u00e9 Laval , Quebec ,","place":["Canada"]},{"name":"Department of Pharmacy, Quebec Mental Health University Institute , Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5227-0721","authenticated-orcid":false,"given":"Ellenor","family":"Mittendorfer-Rutz","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U","family":"Correll","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Charit\u00e9 Universit\u00e4tsmedizin , Berlin ,","place":["Germany"]},{"name":"Department of Psychiatry, The Zucker Hillside Hospital , Glen Oaks, NY"},{"name":"Department of Psychiatry and Molecular Medicine, Donald and Barbara School of Medicine at Hofstra\/Northwell , Hempstead, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0400-6798","authenticated-orcid":false,"given":"Jari","family":"Tiihonen","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital , Kuopio ,","place":["Finland"]},{"name":"Department of Clinical Neuroscience, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Center for Psychiatry Research, Stockholm City Council , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3281-934X","authenticated-orcid":false,"given":"Heidi","family":"Taipale","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital , Kuopio ,","place":["Finland"]},{"name":"Department of Clinical Neuroscience, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Center for Psychiatry Research, Stockholm City Council , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"issue":"1","key":"2024110900301332500_CIT0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881119889296","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology","volume":"34","author":"Barnes","year":"2020","journal-title":"J Psychopharmacol."},{"issue":"5","key":"2024110900301332500_CIT0002","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"Galletly","year":"2016","journal-title":"Aust N Z J Psychiatry."},{"issue":"6","key":"2024110900301332500_CIT0003","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/0269881116636545","article-title":"Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology","volume":"30","author":"Goodwin","year":"2016","journal-title":"J Psychopharmacol."},{"issue":"9","key":"2024110900301332500_CIT0004","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am J Psychiatry."},{"issue":"2","key":"2024110900301332500_CIT0005","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"issue":"2","key":"2024110900301332500_CIT0006","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/wps.20516","article-title":"What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia","volume":"17","author":"Correll","year":"2018","journal-title":"World Psychiatry."},{"key":"2024110900301332500_CIT0007","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther Clin Risk Manag."},{"issue":"1","key":"2024110900301332500_CIT0008","doi-asserted-by":"crossref","first-page":"SU21024IP","DOI":"10.4088\/JCP.SU21024IP1","article-title":"Emerging treatments in schizophrenia","volume":"83","author":"Correll","year":"2022","journal-title":"J Clin Psychiatry."},{"issue":"20","key":"2024110900301332500_CIT0009","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs."},{"issue":"10202","key":"2024110900301332500_CIT0010","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet."},{"key":"2024110900301332500_CIT0011","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.schres.2021.08.013","article-title":"Prolactin levels influenced by antipsychotic drugs in schizophrenia: a systematic review and network meta-analysis","volume":"237","author":"Zhu","year":"2021","journal-title":"Schizophr Res."},{"issue":"2","key":"2024110900301332500_CIT0012","first-page":"131","article-title":"Hyperprolactinemia, clinical considerations, and infertility in women on antipsychotic medications","volume":"51","author":"Edinoff","year":"2021","journal-title":"Psychopharmacol Bull."},{"issue":"47","key":"2024110900301332500_CIT0013","doi-asserted-by":"crossref","first-page":"e1967","DOI":"10.1097\/MD.0000000000001967","article-title":"Bone mineral density in schizophrenia: an update of current meta-analysis and literature review under guideline of PRISMA","volume":"94","author":"Tseng","year":"2015","journal-title":"Medicine (Baltim)."},{"issue":"1","key":"2024110900301332500_CIT0014","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/schbul\/sbac152","article-title":"Antipsychotic use and risk of low-energy fractures in people with schizophrenia: a nationwide nested case-control study in Finland","volume":"49","author":"Solmi","year":"2023","journal-title":"Schizophr Bull."},{"issue":"4","key":"2024110900301332500_CIT0015","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamapsychiatry.2017.4748","article-title":"Association of schizophrenia with the risk of breast cancer incidence: a meta-analysis","volume":"75","author":"Zhuo","year":"2018","journal-title":"JAMA Psychiatry."},{"issue":"3","key":"2024110900301332500_CIT0016","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1176\/appi.ps.201900318","article-title":"Breast cancer screening in women with schizophrenia: a systematic review and meta-analysis","volume":"71","author":"Hwong","year":"2020","journal-title":"Psychiatr Serv."},{"issue":"1","key":"2024110900301332500_CIT0017","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S2215-0366(19)30414-6","article-title":"Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people","volume":"7","author":"Solmi","year":"2020","journal-title":"Lancet Psychiatry."},{"issue":"1","key":"2024110900301332500_CIT0018","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12888-019-2332-z","article-title":"Mortality of site-specific cancer in patients with schizophrenia: a systematic review and meta-analysis","volume":"19","author":"Ni","year":"2019","journal-title":"BMC Psychiatry"},{"issue":"11","key":"2024110900301332500_CIT0019","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.7150\/ijbs.21635","article-title":"Risk factors and preventions of breast cancer","volume":"13","author":"Sun","year":"2017","journal-title":"Int J Biol Sci."},{"issue":"5","key":"2024110900301332500_CIT0020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/09513590.2022.2047173","article-title":"Impact of the prolactin levels in breast cancer: a systematic review and meta-analysis","volume":"38","author":"Aranha","year":"2022","journal-title":"Gynecol Endocrinol."},{"key":"2024110900301332500_CIT0021","doi-asserted-by":"crossref","first-page":"910978","DOI":"10.3389\/fendo.2022.910978","article-title":"Prolactin: the third hormone in breast cancer","volume":"13","author":"Schuler","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2024110900301332500_CIT0022","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/acps.12459","article-title":"Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review","volume":"133","author":"De Hert","year":"2016","journal-title":"Acta Psychiatr Scand."},{"key":"2024110900301332500_CIT0023","doi-asserted-by":"crossref","first-page":"115287","DOI":"10.1016\/j.psychres.2023.115287","article-title":"Breast cancer risks following antipsychotic use in women with bipolar disorder versus schizophrenia: a territory-wide nested case-control study spanning two decades","volume":"326","author":"Chu","year":"2023","journal-title":"Psychiatry Res."},{"key":"2024110900301332500_CIT0024","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1017\/S2045796022000476","article-title":"Association of antipsychotic use with breast cancer: a systematic review and meta-analysis of observational studies with over 2 million individuals","volume":"31","author":"Leung","year":"2022","journal-title":"Epidemiol Psychiatr Sci."},{"issue":"1","key":"2024110900301332500_CIT0025","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/1055-9965.EPI-19-0776","article-title":"Psychotropic medication use and postmenopausal breast cancer risk","volume":"29","author":"George","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"9","key":"2024110900301332500_CIT0026","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1111\/bcp.13661","article-title":"Use of antipsychotics and risk of breast cancer: a Danish nationwide case-control study","volume":"84","author":"Pottegard","year":"2018","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"2024110900301332500_CIT0027","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/JCP.0000000000001513","article-title":"Risk of breast cancer with prolactin elevating antipsychotic drugs: an observational study of US women (ages 18-64 years)","volume":"42","author":"Rahman","year":"2022","journal-title":"J Clin Psychopharmacol."},{"issue":"12","key":"2024110900301332500_CIT0028","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archpsyc.59.12.1147","article-title":"Dopamine antagonists and the development of breast cancer","volume":"59","author":"Wang","year":"2002","journal-title":"Arch Gen Psychiatry."},{"issue":"12","key":"2024110900301332500_CIT0029","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/archpsyc.64.12.1368","article-title":"Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study","volume":"64","author":"Hippisley-Cox","year":"2007","journal-title":"Arch Gen Psychiatry."},{"key":"2024110900301332500_CIT0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.schres.2017.01.019","article-title":"Female schizophrenia patients and risk of breast cancer: a population-based cohort study","volume":"188","author":"Wu Chou","year":"2017","journal-title":"Schizophr Res."},{"issue":"10","key":"2024110900301332500_CIT0031","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S2215-0366(21)00241-8","article-title":"Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland","volume":"8","author":"Taipale","year":"2021","journal-title":"Lancet Psychiatry."},{"key":"2024110900301332500_CIT0032","author":"Matthews"},{"key":"2024110900301332500_CIT0033","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.psyneuen.2015.04.011","article-title":"Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"58","author":"Chen","year":"2015","journal-title":"Psychoneuroendocrinology."},{"issue":"Suppl 2","key":"2024110900301332500_CIT0034","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","article-title":"Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinology."},{"key":"2024110900301332500_CIT0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12911-015-0140-z","article-title":"From prescription drug purchases to drug use periods - a second generation method (PRE2DUP)","volume":"15","author":"Tanskanen","year":"2015","journal-title":"BMC Med Inform Decis Mak."},{"issue":"5","key":"2024110900301332500_CIT0036","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/bcpt.12946","article-title":"Considerations for pharmacoepidemiological studies of drug-cancer associations","volume":"122","author":"Pottegard","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol."},{"issue":"2","key":"2024110900301332500_CIT0037","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/pds.4145","article-title":"New use of prescription drugs prior to a cancer diagnosis","volume":"26","author":"Pottegard","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"10204","key":"2024110900301332500_CIT0038","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2019","journal-title":"Lancet."},{"issue":"17","key":"2024110900301332500_CIT0039","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer - Epidemiology, risk factors, classification, prognostic markers, and current treatment strategies - an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2024110900301332500_CIT0040","doi-asserted-by":"crossref","first-page":"609901","DOI":"10.3389\/fphar.2021.609901","article-title":"Association between antihypertensive medication use and breast cancer: a systematic review and meta-analysis","volume":"12","author":"Xie","year":"2021","journal-title":"Front Pharmacol."},{"issue":"467","key":"2024110900301332500_CIT0041","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/apa.13102","article-title":"Breastfeeding and maternal health outcomes: a systematic review and meta-analysis","volume":"104","author":"Chowdhury","year":"2015","journal-title":"Acta Paediatr."},{"issue":"3","key":"2024110900301332500_CIT0042","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11102-009-0214-y","article-title":"The risk for breast cancer is not evidently increased in women with hyperprolactinemia","volume":"13","author":"Dekkers","year":"2010","journal-title":"Pituitary."},{"key":"2024110900301332500_CIT0043","first-page":"bqac122","article-title":"Breast cancer and prolactin - new mechanisms and models","volume":"163","author":"Clevenger","year":"2022","journal-title":"Periodical."},{"issue":"3","key":"2024110900301332500_CIT0044","first-page":"243","article-title":"Antipsychotic treatment, prolactin, and breast tumorigenesis","volume":"28","author":"De Hert","year":"2016","journal-title":"Psychiatr Danub."},{"issue":"1","key":"2024110900301332500_CIT0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13058-023-01618-3","article-title":"Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers","volume":"25","author":"Hathaway","year":"2023","journal-title":"Breast Cancer Res."},{"issue":"4","key":"2024110900301332500_CIT0046","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/0092623X.2011.606884","article-title":"Subjective quality of life and sexual dysfunction in outpatients with schizophrenia or schizoaffective disorder","volume":"39","author":"Bushong","year":"2013","journal-title":"J Sex Marital Ther."},{"issue":"11","key":"2024110900301332500_CIT0047","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.jsxm.2016.08.011","article-title":"Sexual satisfaction and the importance of sexual health to quality of life throughout the life course of U.S. adults","volume":"13","author":"Flynn","year":"2016","journal-title":"J Sex Med."},{"issue":"4","key":"2024110900301332500_CIT0048","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/00926230390195524","article-title":"A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance","volume":"29","author":"Rosenberg","year":"2003","journal-title":"J Sex Marital Ther."},{"issue":"12","key":"2024110900301332500_CIT0049","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/14737175.2023.2281399","article-title":"Managing antipsychotic-related sexual dysfunction in patients with schizophrenia","volume":"23","author":"Silva","year":"2023","journal-title":"Expert Rev Neurother."},{"issue":"6","key":"2024110900301332500_CIT0050","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/09638237.2019.1581333","article-title":"Sexual dysfunction in patients with schizophrenia and schizoaffective disorder and its association with adherence to antipsychotic medication","volume":"29","author":"Souaiby","year":"2020","journal-title":"J Ment Health."}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/advance-article-pdf\/doi\/10.1093\/schbul\/sbae058\/60543815\/sbae058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/advance-article-pdf\/doi\/10.1093\/schbul\/sbae058\/60543815\/sbae058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:31:46Z","timestamp":1731112306000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/50\/6\/1471\/7660189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,4,30]]},"published-print":{"date-parts":[[2024,11,8]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbae058","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,4,30]]}}}